December 2-4, 2025 | Boston, MA

Panel Discussion Increasing Chemical Diversity in RNA-Targeted Splice Modulator Small Molecules to Expand the Target Space & Address Previously Undruggable Diseases

Time: 1:00 pm
day: Conference Day One

Details:

• How can expanding the target space beyond the common splice modulators unlock new opportunities for targeting novel disease areas

• What strategies are enabling the design of chemically diverse scaffolds to overcome current limitations in the ligand design space

• Are we overdependent on nonsense-mediated decay and can reducing this reliance drive broaden therapeutic applicability of splice modulators

• What lessons can be drawn from recent investments and platform development to guide future innovation in RNA-targeted small molecules

Speakers:

Matt Woll

Dominic Reynolds As Chief Scientific Officer, Dominic is stoked to be a part of building Remix from the ground up, leading the design and synthesis of compounds Read more

Peng Yue A computational biologist with a strong interest in improving human health through engineering drug discovery process. Over 18 years of hands-on biotech experience specializing in Read more

Perla Breccia Medicinal chemist and drug discovery leader with over 20 years experience. Worked in CRO, Pharma & Biotech in various disease areas and more recently focus Read more

Shunichi Kashida Shunnichi Kashida is a pioneer in RNA-targeted small molecule drug discovery and co-founder/CEO of xFOREST Therapeutics. With a PhD in RNA structural biology and synthetic Read more

Thomas Wynn A medicinal chemist with over 20 years of experience in small molecule drug discovery in both pharmaceutical and biotech companies. I have extensive experience in Read more